OR WAIT 15 SECS
Lonza has inaugurated its first ADC payload manufacturing suite at the Visp, Switzerland site.
Lonza has revealed, in a Nov. 5, 2020 press release, that the first manufacturing suite at the company’s Visp, Switzerland site dedicated to the manufacture of antibody-drug conjugate (ADC) drug-linker (payload) is open.
The new highly-potent API suite has been in operation since March 2020. Dedicated to the manufacturing platform for ADC drug-linkers, the first suite handles compounds with occupational exposure levels down to 1 ng/m3. Lonza has reported that a second suite for similar development and manufacturing programs will be available to customers early in 2021.
“Supply from the facility is critical, and by supporting one of our global partners in the oncology field, we are enabling the treatment of many cancer patients,” said Maurits Janssen, strategic business development Small Molecules, Lonza, in the press release. “Oncology continues to be the leading indication in biopharma and a key driver for highly potent ingredients such as antibody-drug conjugates. We continue to add capabilities and capacity to meet the development and manufacturing needs of our partners in this field to answer to their increasing demand.”
“This partnership is a great example of how we can support both early and commercial-stage biopharmaceutical companies through innovation in manufacturing technology and flexible business models,” added Gordon Bates, president Small Molecules, Lonza, in the press release. “Our customers developing highly potent and increasingly complex medicines need a partner whom they can trust to handle these toxic substances throughout their lifecycle and to deliver in sync with their needs, whether for clinical or for commercial supply. Our partner has recognized the value in combining expertise in biologics and chemistry on one site and this investment has expanded our collaboration.”